Par Responds To Process Patents: FineTech Acquisition Valued At $109 Mil.
Par's acquisition of ISP's FineTech chemical business reflects the generic drug company's desire to gain greater control over all aspects of the manufacturing process in the current environment of patent disputes
You may also be interested in...
FDA expects to complete its review of data submitted by AstraZeneca regarding the long-term stability of omeprazole generics in a month.
A dispute between Par and Barr over generic exclusivity for flecainide reflects the continued complexities in the Waxman/Hatch process that could drive Congressional action over the next 18 months.
Par is looking to add branded products to its portfolio as it seeks to join the top-tier independent generic drug companies after Merck KGaA divests its controlling interest in the firm.